Sciampa M (12.5/500mg) 14 Tablets
Empagliflozin 12.5mg and Metformin 500mg for type 2 diabetes.
Sciampa M 12.5/500mg is a fixed-dose combination of empagliflozin 12.5mg (SGLT2 inhibitor) and metformin 500mg. Empagliflozin reduces renal glucose reabsorption; metformin reduces hepatic glucose production. Used for type 2 diabetes as an adjunct to diet and exercise. Usually taken twice daily with meals. Pack of 14 tablets.
Purpose
Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.
Ingredients
Empagliflozin 12.5mg and Metformin hydrochloride 500mg per tablet.
Warnings
Contraindicated in severe renal impairment (eGFR <45), diabetic ketoacidosis. Risk of lactic acidosis. Not for type 1 diabetes.
Side Effects
Genital and urinary tract infections, nausea, diarrhea. Rare: lactic acidosis (metformin), ketoacidosis.
Storage Instructions
Store below 25°C in a dry place. Keep in original pack to protect from moisture.
| Brand | Scilife |
| Status | Active |
Related Products
